GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Teva Pharmaceutical Industries Ltd (WBO:TEVA) » Definitions » Shares Outstanding (EOP)

Teva Pharmaceutical Industries (WBO:TEVA) Shares Outstanding (EOP) : 1,133 Mil (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Teva Pharmaceutical Industries Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Teva Pharmaceutical Industries's shares outstanding for the quarter that ended in Sep. 2024 was 1,133 Mil.

Teva Pharmaceutical Industries's quarterly shares outstanding increased from Jun. 2024 (1,133 Mil) to Sep. 2024 (1,133 Mil). It means Teva Pharmaceutical Industries issued new shares from Jun. 2024 to Sep. 2024 .

Teva Pharmaceutical Industries's annual shares outstanding increased from Dec. 2022 (1,111 Mil) to Dec. 2023 (1,121 Mil). It means Teva Pharmaceutical Industries issued new shares from Dec. 2022 to Dec. 2023 .


Teva Pharmaceutical Industries Shares Outstanding (EOP) Historical Data

The historical data trend for Teva Pharmaceutical Industries's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Teva Pharmaceutical Industries Shares Outstanding (EOP) Chart

Teva Pharmaceutical Industries Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,092.19 1,096.51 1,103.33 1,110.90 1,121.09

Teva Pharmaceutical Industries Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,120.97 1,121.09 1,132.64 1,132.91 1,133.05

Competitive Comparison of Teva Pharmaceutical Industries's Shares Outstanding (EOP)

For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Teva Pharmaceutical Industries's Shares Outstanding (EOP) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Teva Pharmaceutical Industries's Shares Outstanding (EOP) falls into.



Teva Pharmaceutical Industries Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Teva Pharmaceutical Industries  (WBO:TEVA) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Teva Pharmaceutical Industries Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Teva Pharmaceutical Industries's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Teva Pharmaceutical Industries Business Description

Address
124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.